Steven Cohen's CSTL Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 357,317 shares of Castle Biosciences, Inc. (CSTL) worth $8.52 M, representing 0.01% of the portfolio. First purchased in 2020-Q1, this long-term strategic position has been held for 23 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in CSTL, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2024, adding 445,415 shares. Largest reduction occurred in Q2 2022, reducing 623,291 shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Castle Biosciences (CSTL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Castle Biosciences (CSTL) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +357,317 | New Buy | 357,317 | $23.85 |
| Q1 2026 | -119,458 | Sold Out | 0 | $0.00 |
| Q4 2025 | -217,500 | Reduce 64.55% | 119,458 | $38.90 |
| Q3 2025 | +336,958 | New Buy | 336,958 | $22.77 |
| Q2 2025 | -236,218 | Sold Out | 0 | $0.00 |
| Q1 2025 | -310,886 | Reduce 56.82% | 236,218 | $20.02 |
| Q4 2024 | +47,912 | Add 9.60% | 547,104 | $26.65 |
| Q3 2024 | +445,415 | Add 828.26% | 499,192 | $28.52 |
| Q2 2024 | +53,777 | New Buy | 53,777 | $21.77 |
| Q4 2023 | -44,200 | Sold Out | 0 | $0.00 |
| Q3 2023 | +44,200 | New Buy | 44,200 | $16.89 |
| Q2 2023 | -284,847 | Sold Out | 0 | $0.00 |
| Q1 2023 | +83,466 | Add 41.45% | 284,847 | $22.72 |
| Q4 2022 | +201,381 | New Buy | 201,381 | $23.54 |
| Q2 2022 | -623,291 | Sold Out | 0 | $0.00 |
| Q1 2022 | +140,439 | Add 29.09% | 623,291 | $44.86 |
| Q4 2021 | +379,673 | Add 367.98% | 482,852 | $42.87 |
| Q3 2021 | +103,179 | New Buy | 103,179 | $66.50 |
| Q1 2021 | -81,145 | Sold Out | 0 | $0.00 |
| Q4 2020 | +81,145 | New Buy | 81,145 | $67.15 |
| Q3 2020 | -44,022 | Sold Out | 0 | $0.00 |
| Q2 2020 | +16,462 | Add 59.73% | 44,022 | $37.69 |
| Q1 2020 | +27,560 | New Buy | 27,560 | $29.83 |
Steven Cohen's Castle Biosciences Investment FAQs
Steven Cohen first purchased Castle Biosciences, Inc. (CSTL) in Q1 2020, acquiring 27,560 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Castle Biosciences, Inc. (CSTL) for 23 quarters since Q1 2020.
Steven Cohen's largest addition to Castle Biosciences, Inc. (CSTL) was in Q3 2024, adding 499,192 shares worth $14.24 M.
According to the latest 13F filing for Q2 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 357,317 shares of Castle Biosciences, Inc. (CSTL), valued at approximately $8.52 M.
As of the Q2 2026 filing, Castle Biosciences, Inc. (CSTL) represents approximately 0.01% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Castle Biosciences, Inc. (CSTL) was 623,291 shares, as reported at the end of Q1 2022.